Stuart Isaacson, MD, FAAN, Parkinson Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, comments on the benefits of having treatment options, such as SEP-363856, for Parkinson’s disease (PD) psychosis. Many PD patients develop psychotic symptoms at a very early stage, and the symptoms worsen over time. Currently, there is only one on-label first-line medication that can treat psychosis without compromising the motor symptoms treatment. Therefore, if SEP-363856 becomes commercially available, it will play an important role in PD psychosis treatment. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.